After stopping semaglutide: research, reviews and practical support
If you are considering stopping semaglutide, start with the clinician who prescribes it. Ask what stopping means for the condition being treated, how follow-up will work and who to contact if you become unwell. An article cannot decide whether you should stop, continue or restart.
What the weight-regain research actually studied
The STEP 1 extension followed a subset of adults without diabetes after a trial of weekly semaglutide 2.4 mg. Both medicine and the trial's lifestyle intervention ended after 68 weeks. The extension assessed participants for another year.
Average weight regain occurred after treatment ended, and several cardiometabolic improvements moved back towards their starting levels. This was an exploratory follow-up of 327 participants. It was not a study exclusively of UK men, a SHIFT programme study or a forecast of what every person taking Ozempic will experience.
That distinction matters. A result from a specific dose and trial population cannot be turned into a claim that every man will regain a particular percentage within a year. Nor does this study prove that a particular commercial aftercare programme will prevent regain.
Read the original STEP 1 extension paper for the population, treatment and follow-up details. Use it to prepare questions for your prescriber, rather than treating an average as your future.
Questions to settle before a change
A useful appointment produces an individual plan. Ask:
- Why are we considering stopping, and what alternatives are appropriate for me?
- What should happen to my other treatment, if anything?
- What follow-up or monitoring do you recommend, and when?
- What symptoms or changes should prompt earlier contact?
- If treatment has already stopped, who should review the gap before any restart?
Write down the answers and the contact route. Do not use leftover medicine or a previous dose as a restart plan. Discuss medicine changes with your prescriber.
Keep practical routines manageable
Pick a few routines you can repeat during an ordinary working week. That might mean planning a couple of familiar meals, keeping a regular shopping list and making room for movement you already find manageable. Avoid treating a difficult week as a reason to abandon every routine at once.
Choose one next step you can describe clearly: prepare tomorrow's lunch, arrange a walk with a friend or make the review appointment. A small completed action is more useful than an elaborate plan that does not fit your life.
Keep progress records only if they help. A short note of your routine, questions and how you feel can make follow-up easier. Do not diagnose a problem from a home body-composition estimate or let an app override clinical advice.
What My Timber can help with
My Timber provides everyday support with food, movement, personal goals and progress records. It does not prescribe medicines, decide doses or provide a clinical review. Medicine assessment, prescribing, dispensing and treatment monitoring belong with your appropriately regulated healthcare provider.
You can use My Timber for support with routines whether you use medicine or not. There is no promise that an app, food plan or activity routine will prevent regain or replace the follow-up your clinician recommends.
SHIFT's medicine ordering remains closed while a prescribing partner is being commissioned. This page is information, not an invitation to buy prescription medicine or book a SHIFT prescribing assessment.
If you become unwell
Seek urgent medical help for severe, persistent abdominal pain, particularly if it spreads to your back. The MHRA has strengthened pancreatitis warnings for these medicines. Do not wait for a routine review or an app response.
For other new or persistent symptoms, contact your clinician or pharmacist and follow the advice in the leaflet supplied with your medicine. Tell them what you have taken and when the last dose was.
Sources
- Wilding and colleagues: STEP 1 trial extension, 2022 — original semaglutide withdrawal research and its limitations.
- MHRA: strengthened warnings on acute pancreatitis, January 2026 — urgent symptom guidance.
Editorial correction — 2 October 2026
We replaced an unsupported male-specific weight-regain headline and removed a recommendation linking to compounded medicines, unapproved personal attribution and claims about SHIFT clinical services. Research is identified by its actual population and treatment. This editorial correction is not an independent clinical review or individual medical advice.
Related: Food Noise After Stopping GLP-1 | SHIFT Continuity.
Last updated .
